Science4Tech Solutions (S4T), the scaleup offering value-added services based on SaaS technology and Apps to accelerate the results of clinical trials for the benefit of patients, has secured € 2M in first round investment the last quarter of 2022. Fifty private investors have partnered with Science4Tech Solutions to improve and speed up access to cancer clinical trials, bringing hope to patients and families when conventional treatments are no longer effective.
The capital increase has allowed S4T to grow from being an emerging company to a scaleup with exponential business progression and scalability, assuming new challenges for the benefit of the final patient. Through its flagship technological solution, MatchTrial®, ST4 consolidates its mission aimed at providing more options for cancer patients.
For S4T, investment in research and technology is key to achieve business objectives. Accordingly, €300,000 will be allocated to this objective thanks to the granting of a participatory loan through ENISA. Obtaining this financing reinforces and endorses the business model, its innovative approach, and the sustainability of the project.
The capitalization of S4T will allow the Board of Directors and General Management to address another stage of the company in the Healthtech field and to strengthen itself in this stage of growth. The company has already undergone an internal reorganization with the appointment of Jordi Guitart as the new CEO. He takes over for David Campos who has led the investment round and will continue to be linked to the project as a member of the Board of Directors on behalf of minority shareholders. On the other hand, the organization has been reinforced with new talent and capabilities in technology, Artificial Intelligence, Big Data, etc.
The founders of S4T María Campos, Dr. Antonio Llombart and Dr. Javier Cortés, who are leaders in the field of biomedical and oncological research, have a clear mission: “To transform research through technology for the benefit of the patient”. Not only have they accelerated the process, but they have also improved the efficiency in timing and location. To do this, the challenge is to have the necessary training and professionalization to expand its reach in providing research and innovative solutions to other high-impact diseases and expand to new territories such as France and the USA, which will ultimately aid in helping more patients suffering from cancer and other pathologies through the development of novel solutions.
There are 4 main objectives of S4T in 2023: internationalization, development of new technological solutions, training of the organization through bringing on new talent and launch of an international institutional round scheduled for the last quarter of the year.
It should also be noted that S4T has recently closed an advisory agreement with Diagonal Asset Management to successfully strength its growth plan.
S4T positions itself as a new player in this field with a value proposition that has managed to unite a top-level ecosystem in the clinical field with the effective collaboration of more than 300 hospitals and research centers, as well as the participation of more than 30 patient associations.